Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study

Allison M Bock; Jennifer J Gile; Melissa C Larson; Kittika Poonsombudlert; Reema K Tawfiq; Seth Maliske; Matthew J Maurer; Brian F Kabat; Jonas Paludo; David J Inwards; Sabarish Ayyappan; Brian K Link; Stephen M Ansell; Thomas M Habermann; Thomas E Witzig; Grzegorz S Nowakowski; James R Cerhan; Umar Farooq; Yucai Wang

doi:10.1038/s41408-023-00942-3

$Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study$

Journal article

Open access

Peer reviewed

Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study

Allison M Bock, Jennifer J Gile, Melissa C Larson, Kittika Poonsombudlert, Reema K Tawfiq, Seth Maliske, Matthew J Maurer, Brian F Kabat, Jonas Paludo, David J Inwards, …

Blood cancer journal (New York), Vol.13(1), 169

11/13/2023

DOI: 10.1038/s41408-023-00942-3

PMCID: PMC10643454

PMID: 37957158

Files and links (1)

url

https://doi.org/10.1038/s41408-023-00942-3View

Published (Version of record) Open Access

Abstract

Over the last two decades, the frontline therapy for mantle cell lymphoma (MCL) has evolved. However, the impact of subsequent lines of therapy on survival outcomes has not been well characterized. In this study, we investigated the treatment patterns and survival outcomes in patients with relapsed/refractory (R/R) MCL treated with second-line (2 L) therapy. Adult patients with newly diagnosed MCL from 2002 to 2015 were enrolled in a prospective cohort study. Clinical characteristics, 2 L treatment details, and outcomes were compared between patients who received 2 L treatment between 2003–2009 (Era 1), 2010–2014 (Era 2), and 2015–2021 (Era 3). 2 L treatment was heterogenous in all eras, and there was a substantial shift in the pattern of 2 L therapy over time. The estimated 2-year EFS rate was 21% (95% CI, 13–35), 40% (95% CI, 30–53), and 51% (95% CI, 37–68) in Era 1–3 respectively, and the 5-year OS rate was 31% (95% CI, 21–45), 37% (95% CI, 27–50), and 67% (95% CI, 54–83) in Era 1–3, respectively. These results provide real-world evidence on evolving treatment patterns of 2 L therapy based on the era of relapse. The changes in 2 L treatment correlated with improved EFS and OS, suggesting that treatment advances are associated with improved outcomes in patients with R/R MCL.

Cohort Analysis

Lymphoma

Details

Title: Subtitle: Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study
Creators: Allison M Bock - Mayo Clinic
Jennifer J Gile - Mayo Clinic
Melissa C Larson - Mayo Clinic in Florida
Kittika Poonsombudlert - Mayo Clinic in Florida
Reema K Tawfiq - Mayo Clinic
Seth Maliske - Sanford Health
Matthew J Maurer
Brian F Kabat - Mayo Clinic in Florida
Jonas Paludo - Mayo Clinic
David J Inwards - Mayo Clinic in Florida
Sabarish Ayyappan - University of Iowa
Brian K Link - University of Iowa
Stephen M Ansell - Mayo Clinic
Thomas M Habermann - Mayo Clinic
Thomas E Witzig - Mayo Clinic
Grzegorz S Nowakowski - Mayo Clinic
James R Cerhan - Mayo Clinic
Umar Farooq - University of Iowa
Yucai Wang - Mayo Clinic
Resource Type: Journal article
Publication Details: Blood cancer journal (New York), Vol.13(1), 169
DOI: 10.1038/s41408-023-00942-3
PMID: 37957158
PMCID: PMC10643454
NLM abbreviation: Blood Cancer J
ISSN: 2044-5385
eISSN: 2044-5385
Publisher: Springer Nature B.V
Grant note: name: NIH, NCI
Language: English
Date published: 11/13/2023
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Epidemiology; Internal Medicine
Record Identifier: 9984511760202771

Metrics

54 Record Views

6 Times Cited - Web of Science